Former Chief Financial Officer · Axsome Therapeutics, Inc. (AXSM)

John Golubieski

A named executive officer of Axsome Therapeutics in every fiscal year CompBrief holds from FY2017 to FY2017. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2017

$750,448

Salary $131,875Stock awards $0Bonus $50,000

2nd of 2 named executive officers at Axsome Therapeutics by FY2017 total.

2 named officers on file for Axsome Therapeutics, FY2017

John Golubieski’s pay file — $29

  • 2 fiscal years of pay, line by line
  • AXSM’s disclosed peer group of 16 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Axsome Therapeutics’s whole pay program stands against its peers

  • Axsome Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AXSM→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2019 (DEF 14A).

Free

Get John Golubieski’s full pay file as a PDF — free

More than this page: up to 10 years of John’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

John Golubieski compensation by year

Axsome Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Axsome Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2017FY2018
Salary$131,875$115,833
Bonus$50,000$-50,000
Stock awards$0$0
Option awards$519,616$0
Non-equity incentive$48,957$0
Pension and deferred compensation$0$0
All other$0$0
Total$750,448$65,833

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Axsome Therapeutics, Inc. DEF 14A filed April 26, 2019, accession 0001558370-19-003404, and prior-year filings.

How this page was built: the Axsome Therapeutics, Inc. filed document, accession 0001558370-19-003404. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2019.

$750K
$66K
FY17
FY18
SalaryBonusNon-equity incentiveOption awards

Axsome Therapeutics’s named executive officers, FY2017

as the company reported each
Named executive officerRoleFY2017 total
Herriot TabuteauChief Executive Officer and Chairman of the Board$1,123,352
John Golubieski · this pageFormer Chief Financial Officer$750,448

The full Axsome Therapeutics compensation record

free company brief

This page is one person within Axsome Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Axsome Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

John Golubieski's compensation dossier · One-time report. No refunds.